Patent intelligence · US
US 9987326
Klotho protein and related compounds for the treatment and diagnosis of cancer
Klotho protein and related compounds for the treatment and diagnosis of cancer
Patent details — US 9987326
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 5, 2018
- Expiration
- May 31, 2038
- Claims
- 10
- CPC classes
- A61K, A61K38/1709, A61P, A61P35/00
Quick answer
US 9987326 (Klotho protein and related compounds for the treatment and diagnosis of cancer) is held by TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.. Status: granted. Granted Jun 5, 2018. Expires May 31, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K38/1709, A61P, A61P35/00
More from TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12279630
Treatment and prevention of seed allergies
granted -
US 12251417
Antimicrobial compounds from the genus Delftia
granted -
US 12139522
T-cells comprising two different chimeric antigen receptors and uses thereof
granted -
US 12134650
Compositions targeting GABRA2 and methods for diagnosis and treatment of cancer
granted -
US 12084350
Allotrope of carbon having increased electron delocalization
granted -
US 12023348
EGR1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions
granted -
US 11944644
T-cells comprising anti-CD38 and anti-CD138 chimeric antigen receptors and uses thereof
granted -
US 11932871
Methods of culturing t cells and uses of same
granted
Frequently asked questions
What is US patent 9987326?
US 9987326 (Klotho protein and related compounds for the treatment and diagnosis of cancer) is held by TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.. Status: granted. Granted Jun 5, 2018. Expires May 31, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9987326?
TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 93 pharmaceutical patents for this assignee.
When does US 9987326 expire?
Our index shows an expiration date of May 31, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.